Sensorion Announces Appointment of New Chief Financial Officer

Montpellier, June 27, 2024 - Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company focused on innovative therapies for hearing loss disorders, has named Laurene Danon as its new Chief Financial Officer.

Danon brings over 15 years of experience in investment banking and equity capital markets. A graduate of HEC, her career includes roles at J.P. Morgan and Jefferies International before founding Concorde Advisory. She has managed over 70 transactions, raising more than $35 billion.

Previously advising Sensorion on capital increases, Danon expressed enthusiasm about joining Sensorion during a pivotal period marked by advancements in its gene therapy programs.

Nawal Ouzren, CEO of Sensorion, highlighted Danon's significant expertise in international capital markets as a vital addition to the team to support the company's mission to develop therapies for hearing disorders.